<DOC>
	<DOCNO>NCT01890200</DOCNO>
	<brief_summary>This randomize , double blind , multi-center , placebo control , three parallel arm , Phase IIb/III clinical study evaluate effect add TCM-700C low high dose onto combination treatment ( PegIFN plus RBV ) subject naive genotype 1 HCV infection . This demonstrate high sustained virologic response rate , define absence detectable HCV RNA 24 week termination combination treatment , compare placebo add-on .</brief_summary>
	<brief_title>The Effects Adding TCM-700C Standard Combination Treatment HCV Genotype 1 Patients ( Phase III )</brief_title>
	<detailed_description>Eligible subject write informed consent stratify accord baseline HCV RNA ( ≤800,000 IU/mL versus &gt; 800,000 IU/mL ) , stage liver fibrosis ( METAVIR system fibrosis score 0 1 versus 2 3 ) . During 48 week Treatment Period 24 week Follow Period , subject assess regular interval efficacy safety Weeks 2 , 4 , 8 , 12 , 16 every 8 week thereafter study completion . If possible , subject prematurely discontinue study Treatment Period sample take hematology , biochemistry urinalysis week discontinuation well 24 week discontinuation .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult subject 20 65 year old ( inclusive ) , either gender ethnical group Asia . Chronic hepatitis C , positive antibody hepatitis C virus ( anti HCV ) HCV RNA assay . Confirmed HCV genotype 1 . Subjects indicated combination treatment PegIFNα 2a RBV discretion investigator . All fertile male female receive RBV must use two form effective contraception treatment study drug 6 month post treatment completion . Subjects must voluntarily give write informed consent indicate understand purpose procedure require study willing participate study . Subjects must able comply assessment study . Subjects must able understand study QoL questionnaire . Prior treatment IFN α medicine contain Cordyceps . Prior treatment hepatitis C antiviral immune modulators . Investigational therapy administer within 4 week , within time interval less least 5 half life investigational agent , whichever longer , prior first schedule day dose study . Subjects diagnose hepatocellular carcinoma ( HCC ) biopsy α fetoprotein ( AFP ) serology radiology ( helical compute tomography [ CT ] and/or magnetic resonance image [ MRI ] ) within 5 year sign informed consent form . Evidence hepatic decompensation ( history current evidence ascites , bleed varix hepatic encephalopathy ) . History evidence liver diseases chronic HCV infection . Subjects know allergy hypersensitivity ingredient study drug placebo . Pregnant , plan become pregnant , breastfeed female subject male subject whose partner pregnant planning become pregnant . Subject follow laboratory abnormality : 1 . Platelet count &lt; 90,000/mm3 ; 2 . Absolute neutrophil count &lt; 1500 cells/mm3 ; 3 . Hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; 4 . Creatinine &gt; 1.5 mg/dL ; 5 . Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 10 x upper limit normal ( ULN ) ; 6 . Total serum bilirubin &gt; 1.5 x ULN ; 7 . Subjects without cirrhosis AFP &gt; 50 ng/mL must ultrasound screen baseline visit finding suspicious HCC . Medical condition contraindication PegIFNα 2a RBV therapy : 1 . Psychiatric disorder ; 2 . Organ transplant ( cornea hair transplant skin graft ) ; 3 . Severe concurrent medical disease severe hypertension , significant coronary heart disease , poorly control diabetes mellitus ( glycated hemoglobin A1c [ HbA1c ] &gt; 8.5 % ) , adequately control thyroid dysfunction , chronic obstructive pulmonary disease , severe infection ( bacterial , viral , fungal , include acute tuberculosis ) , hemoglobinopathy ( thalassemia major sickle cell anemia ) ; 4 . Autoimmune hepatitis autoimmune condition know exacerbate PegIFNα 2a RBV . History severe seizure disorder current anticonvulsant use . Evidence severe retinopathy ( e.g. , cytomegalovirus retinitis , macular degeneration ) clinically relevant ophthalmological disorder ( e.g. , due diabetes mellitus hypertension ) . Other case judge investigator ineligible participation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>add-on treatment</keyword>
	<keyword>botanical drug</keyword>
	<keyword>HCV genotype 1</keyword>
	<keyword>TCM-700C</keyword>
</DOC>